Other Neurorheumatologic Conditions
Neurologic complications of systemic rheumatologic diseases represent a diagnostically challenging intersection of two specialties. Rheumatoid arthritis, IgG4-related disease, ANCA-associated vasculitis, relapsing polychondritis, and other systemic inflammatory conditions can all produce significant CNS and PNS manifestations. These neurologic complications are often underrecognized, may occur independently of systemic disease activity, and require tailored immunotherapeutic approaches that frequently fall outside standard rheumatologic treatment guidelines.
Bottom Line
- Rheumatoid arthritis CNS disease is rare: Neurologic complications are most commonly compressive (carpal tunnel, cervical myelopathy); true inflammatory CNS manifestations are exceedingly uncommon and occur late in disease with poor control
- Atlantoaxial instability: Any RA patient presenting with myelopathy signs requires urgent spinal cord imaging to evaluate for C1–C2 subluxation
- IgG4-related disease: CNS involvement occurs in only ~2% of patients, most commonly as hypertrophic pachymeningitis; importantly, CNS disease occurs without systemic manifestations in over 50% of cases
- TNF-alpha inhibitor paradox: These agents (infliximab, adalimumab, etanercept) may increase the risk of CNS demyelination and inflammatory syndromes, particularly in RA patients
- Comorbid autoimmunity: NMOSD patients have a high prevalence of rheumatologic antibodies; treatment should be dictated by the neurologic disease without delay for rheumatologic workup
- Corticosteroids are the cornerstone: Acute treatment for virtually all CNS rheumatologic manifestations begins with corticosteroids; controlled trial data for steroid-sparing agents in this setting are sparse
Rheumatoid Arthritis and the Nervous System
Rheumatoid arthritis (RA) is the most common systemic autoimmune arthropathy, and its neurologic complications are predominantly compressive rather than inflammatory. Carpal tunnel syndrome and cervical spinal cord compression from atlantoaxial disease are the most frequently encountered manifestations. True inflammatory involvement of the CNS — including rheumatoid meningitis, CNS vasculitis, and rheumatoid nodules — is exceedingly uncommon, typically occurs late in disease (often ≥10 years after diagnosis), and is generally seen in the setting of poorly controlled systemic disease. Critically, CNS involvement does not herald disease onset in RA.
Atlantoaxial Instability
The atlantoaxial joint (C1–C2) is the most clinically important site of compressive neurologic disease in RA. Chronic synovial inflammation at this joint leads to pannus formation around the odontoid process, ligamentous laxity, and progressive instability. Patients with greater erosive joint disease and higher anti-cyclic citrullinated peptide (anti-CCP) antibody titers are at increased risk.
Urgent Evaluation Required
- Any RA patient presenting with signs of myelopathy (upper motor neuron signs, gait ataxia, bowel/bladder dysfunction) requires urgent spinal cord imaging
- Evaluate for atlantoaxial subluxation, pannus formation, and spinal cord compression at C1–C2
- Progressive myelopathy may necessitate surgical stabilization
Rheumatoid Meningitis
Rheumatoid meningitis is a rare but important inflammatory CNS complication of RA. It characteristically occurs in patients with a preexisting RA diagnosis, usually of more than 10 years’ duration, with equal male-to-female incidence (unlike RA itself, which is female-predominant).
Rheumatoid Meningitis: Key Features
- Clinical presentation: Focal neurologic signs, headache, fever, weight loss, and malaise
- Laboratory: ~80% have elevated CRP/ESR; ~90% have elevated rheumatoid factor (RF) and anti-CCP antibodies
- CSF: Typically abnormal with pleocytosis and elevated protein; CSF anti-CCP testing may be helpful diagnostically
- MRI: Focal or diffuse meningeal involvement, with frontal and parietal predominance in approximately 80% of cases
- Differential: Infection must be rigorously excluded before attributing meningeal disease to RA
CNS Vasculitis in Rheumatoid Arthritis
CNS vasculitis is a rare, late-stage manifestation of RA affecting small and medium-sized vessels. Serum RA biomarkers (RF, anti-CCP, inflammatory markers) are usually elevated at the time of CNS vasculitis diagnosis. The clinical presentation may include stroke-like episodes, cognitive decline, seizures, or diffuse encephalopathy.
Rheumatoid Nodules
Intracranial rheumatoid nodules rarely present as mass lesions in the CNS. When identified, they are usually associated with concurrent meningeal involvement. Histopathologically, they demonstrate the characteristic palisading granulomatous appearance seen in subcutaneous rheumatoid nodules.
Other Neurologic Associations in RA
- Restless leg syndrome: Pooled prevalence of approximately 25% in RA patients, significantly higher than the general population
- Gastroparesis: Odds ratio of 1.36 in RA compared to controls; younger, female, and Black individuals are disproportionately affected
Treatment of CNS Manifestations in RA
TNF-Alpha Inhibitor Caution in RA
- TNF-alpha inhibitors (infliximab, adalimumab, etanercept) may increase the risk of CNS inflammation in RA patients
- These agents should be avoided in RA patients with known or suspected CNS inflammatory manifestations
- Treatment of CNS manifestations in RA is not addressed in standard RA treatment guidelines
| Agent | Role in RA CNS Disease | Notes |
|---|---|---|
| Corticosteroids | First-line acute treatment | High-dose IV methylprednisolone or oral prednisone |
| Cyclophosphamide | Severe CNS vasculitis or refractory meningitis | IV or oral formulations |
| Methotrexate | Maintenance; first-line for RA per guidelines | 10–25 mg/week; coadminister folic acid 1 mg daily |
| Rituximab | Refractory CNS disease | B-cell depletion therapy |
| Azathioprine | Steroid-sparing maintenance | Check TPMT genotype before initiation |
| Tocilizumab | Alternative steroid-sparing agent | IL-6 receptor inhibitor |
| TNF-alpha inhibitors | AVOID for CNS manifestations | May worsen or trigger CNS inflammation |
IgG4-Related Disease
IgG4-related disease (IgG4-RD) is an immune-mediated fibrosing disorder that can affect virtually any organ system. It is characterized by tumor-like tissue infiltration with IgG4-positive plasma cells and lymphocytes, storiform fibrosis, and often (but not always) elevated serum IgG4 levels. There is a male predilection, with onset typically in the 5th to 6th decade of life.
Systemic Manifestations
Common systemic manifestations of IgG4-RD include:
- Autoimmune pancreatitis (type 1)
- Sclerosing cholangitis
- Sclerosing sialadenitis with lacrimal, parotid, and submandibular gland involvement (Mikulicz disease)
- Orbital pseudotumor — the orbit is the most common head and neck site, affected in ~25% of IgG4-RD patients
- Hypophysitis
- Retroperitoneal fibrosis with or without aortitis
CNS Involvement
CNS involvement occurs in only approximately 2% of IgG4-RD patients. Importantly, CNS disease occurs without systemic manifestations in more than 50% of cases, making diagnosis particularly challenging when the CNS is the presenting site.
Meningeal IgG4-Related Disease
The most common CNS manifestation is hypertrophic or nodular pachymeningitis. Given the slowly progressive nature of the fibroinflammatory process, patients may have relatively minor symptoms despite extensive meningeal disease on imaging.
IgG4 Pachymeningitis: Imaging and CSF Features
- Unenhanced MRI: Meningeal thickening isointense to brain parenchyma
- Post-contrast MRI: Homogeneous meningeal enhancement
- Distribution: May involve both ventral and dorsal spinal meninges, potentially causing progressive myelopathy
- CSF: Pleocytosis is common; oligoclonal bands may be detected
- Rare presentation: Mass lesion within the brain parenchyma
Diagnosis of IgG4-Related Disease
Elevated serum IgG4 is not specific for IgG4-RD and cannot be used alone as a diagnostic criterion. Tissue biopsy demonstrating a characteristic lymphoplasmacytic infiltrate of IgG4-positive plasma cells and lymphocytes with storiform fibrosis, matched with a compatible clinical syndrome, is required for definitive diagnosis.
| Diagnostic Criterion | Details |
|---|---|
| 2019 ACR/EULAR Classification Criteria | Typical organ involvement + exclusion of alternatives + score ≥20 on weighted pathologic/serologic findings |
| Typical organ involvement | Pachymeninges are listed as a typical organ for IgG4-RD classification |
| Histopathology (gold standard) | Lymphoplasmacytic infiltrate with IgG4+ plasma cells, storiform fibrosis, obliterative phlebitis |
| Serum IgG4 | May be elevated but is neither sensitive nor specific; normal in a subset of biopsy-proven cases |
Treatment of IgG4-Related Disease
Corticosteroids are the first-line treatment for IgG4-RD. Steroid-sparing agents are used for maintenance therapy or in steroid-refractory cases. Evidence for CNS-specific treatment is limited to case reports and small case series, as no controlled trials have enrolled patients with CNS IgG4-RD.
- Corticosteroids: First-line; typically high-dose prednisone with gradual taper
- Rituximab: Most commonly used steroid-sparing agent; supported by small open-label trials (though none specifically included CNS patients)
- Mycophenolate mofetil: Alternative steroid-sparing agent
- Leflunomide: Limited data from small open-label trials
TNF-Alpha Inhibitor–Associated Demyelination
TNF-alpha inhibitors — including infliximab, adalimumab, and etanercept — are associated with an increased risk of demyelinating disease and other inflammatory CNS syndromes. This paradoxical complication is more commonly observed in patients with rheumatoid arthritis than in those receiving these agents for other indications.
Management of TNF-Alpha Inhibitor–Associated CNS Disease
- First step: Explore alternative therapies for the underlying rheumatologic disease and discontinue the TNF-alpha inhibitor
- A short course of corticosteroids may be required for acute CNS inflammation
- If active CNS disease persists after stopping the TNF-alpha inhibitor, ongoing immunotherapy directed at the CNS disease is needed
- Do not rechallenge with TNF-alpha inhibitors after a demyelinating event
Comorbid Neurologic and Rheumatologic Autoimmunity
Patients with neuromyelitis optica spectrum disorder (NMOSD) have a high prevalence of concurrent rheumatologic disease and rheumatologic antibodies (ANA, anti-SSA/SSB, anti-dsDNA). Patients with multiple sclerosis demonstrate similar associations, though to a lesser degree.
Managing Overlapping Autoimmunity
- If a patient meets diagnostic criteria for MS, MOGAD, or NMOSD, treatment should be dictated by the neurologic disease
- The presence of rheumatologic antibodies should not delay initiation of high-efficacy neurologic therapy
- Referral to rheumatology is appropriate for evaluation and management of systemic symptoms
- Some immunotherapies (e.g., rituximab, mycophenolate) may simultaneously address both neurologic and rheumatologic disease
ANCA-Associated Vasculitis
The ANCA-associated vasculitides are small vessel necrotizing vasculitides that can produce significant neurologic manifestations, including pachymeningitis.
| Condition | Key Features | Neurologic Manifestations |
|---|---|---|
| Granulomatosis with polyangiitis (GPA) | Small vessel necrotizing vasculitis; granulomatous inflammation of upper/lower respiratory tract; PR3-ANCA (c-ANCA) predominant | Pachymeningitis (hypertrophic); cranial neuropathies; peripheral neuropathy; orbital disease |
| Microscopic polyangiitis (MPA) | Small vessel necrotizing vasculitis without granulomas; MPO-ANCA (p-ANCA) predominant; pauci-immune glomerulonephritis | Peripheral neuropathy (mononeuritis multiplex); less commonly CNS involvement |
| Eosinophilic granulomatosis with polyangiitis (EGPA) | Small vessel vasculitis with asthma, blood eosinophilia, and eosinophilic tissue infiltration | Peripheral neuropathy (most common neurologic feature); cranial neuropathies; rarely CNS vasculitis |
Additional Neurorheumatologic Conditions
Relapsing Polychondritis
Relapsing polychondritis is characterized by recurrent inflammation of cartilaginous tissues throughout the body. The characteristic clinical finding is ear lobe pain with a hyperemic, swollen, and tender ear (auricular chondritis). CNS manifestations include hypertrophic pachymeningitis, meningoencephalitis, and limbic encephalitis.
Polyarteritis Nodosa
Polyarteritis nodosa (PAN) is a small and medium vessel arteritis. Peripheral nervous system involvement (mononeuritis multiplex) is common, but CNS manifestations are rare. Pachymeningitis has been reported in isolated cases.
Cryoglobulinemia
Cryoglobulinemia involves immunoglobulins that precipitate at temperatures below 37°C (typically tested at 4°C). It is associated with malignancies, chronic infections (particularly hepatitis C virus), and connective tissue disorders. Neurologic manifestations include peripheral neuropathy (most common), and less commonly meningitis and CNS vasculitis.
Cogan Syndrome
Cogan syndrome is a systemic vasculitis defined by the combination of ocular keratitis (interstitial keratitis) and vestibuloauditory dysfunction (sensorineural hearing loss, vestibular symptoms). Less commonly, patients develop meningitis and other neurologic symptoms. Systemic vasculitis affecting medium and large vessels (including aortitis) may occur.
General Principles of Treatment
Treatment Approach for CNS Rheumatologic Disease
- Corticosteroids are the cornerstone of acute treatment for all neurorheumatologic conditions discussed in this topic
- Choice of steroid-sparing agent and duration of maintenance therapy is dictated by: the underlying disease, previous treatment exposure, disease severity, and whether it is a first presentation or relapse
- Paucity of controlled trial data: There are no randomized controlled trials specifically addressing CNS manifestations of rheumatologic disease; treatment is guided by case series, extrapolation from systemic disease trials, and expert consensus
- Many immunotherapies used for neurologic indications have dual efficacy for concurrent rheumatologic disease (e.g., rituximab, methotrexate, mycophenolate)
Immunotherapies for Neurorheumatologic Conditions
The following table summarizes the immunotherapeutic agents commonly used in the management of neurologic complications of rheumatologic disease, including dosing, screening requirements, monitoring, and adverse effects.
| Drug | Mechanism | Dosing | Key Screening | Key Monitoring | Common Side Effects |
|---|---|---|---|---|---|
| Prednisone | Broad immunosuppression; inhibits NF-κB and inflammatory cytokines | 60–80 mg/day orally; taper per clinical response | Glucose, blood pressure, bone density (if prolonged use anticipated) | Glucose, blood pressure, weight, bone density, mood | Weight gain, hyperglycemia, osteoporosis, mood changes, insomnia, infection risk |
| IV methylprednisolone (IVMP) | High-potency glucocorticoid | 1 g IV daily × 3–5 days | Glucose, blood pressure | Glucose, blood pressure during infusion | Insomnia, metallic taste, hyperglycemia, hypertension, psychiatric symptoms |
| Methotrexate | Folate antagonist; inhibits lymphocyte proliferation | 10–25 mg/week orally or SC; coadminister folic acid 1 mg daily | CBC, LFTs, renal function, hepatitis B/C serology, chest X-ray | CBC, LFTs every 1–3 months | Nausea, stomatitis, hepatotoxicity, myelosuppression, pneumonitis (rare) |
| Mycophenolate mofetil | Inhibits inosine monophosphate dehydrogenase; suppresses lymphocyte proliferation | 1000–3000 mg/day orally in divided doses | CBC, LFTs, renal function | CBC every 1–3 months | Diarrhea, nausea, myelosuppression, infection risk |
| Azathioprine | Purine synthesis inhibitor; suppresses lymphocyte proliferation | 1–3 mg/kg/day orally | TPMT genotype (mandatory before initiation); CBC, LFTs | CBC, LFTs every 1–3 months | Myelosuppression, hepatotoxicity, nausea, pancreatitis, infection risk |
| Infliximab | Anti-TNF-α monoclonal antibody (chimeric) | 3–5 mg/kg IV at 0, 2, and 6 weeks, then every 4–8 weeks | TB screening (mandatory); hepatitis B/C serology | Infusion reactions; LFTs; signs of infection or demyelination | Infusion reactions, infection risk, risk of CNS demyelination, hepatotoxicity |
| Adalimumab | Anti-TNF-α monoclonal antibody (fully human) | 40 mg SC every 2 weeks | TB screening (mandatory); hepatitis B/C serology | Injection site reactions; signs of infection or demyelination | Injection site reactions, infection risk, risk of CNS demyelination |
| Rituximab | Anti-CD20 monoclonal antibody; B-cell depletion | 1000 mg IV × 2 doses (separated by 2 weeks), then every 6 months | Hepatitis B/C serology, TB screening; IgG levels; CBC | IgG levels (before each cycle); CBC; signs of infection | Infusion reactions, hypogammaglobulinemia, infection risk, PML (rare) |
| Cyclophosphamide (oral) | Alkylating agent; broadly cytotoxic to lymphocytes | 1–2 mg/kg/day orally | CBC, renal function, urinalysis; PCP prophylaxis | CBC weekly initially, then monthly; urinalysis (hemorrhagic cystitis) | Myelosuppression, hemorrhagic cystitis, infection risk, infertility, malignancy risk |
| Cyclophosphamide (IV) | Alkylating agent; broadly cytotoxic to lymphocytes | 500–1000 mg/m2 IV monthly × 3–6 months | CBC, renal function, urinalysis; PCP prophylaxis + mesna | CBC at nadir (10–14 days post-infusion); urinalysis | Myelosuppression, nausea/vomiting, hemorrhagic cystitis (mesna reduces risk), infection risk, infertility |
| Tocilizumab | IL-6 receptor inhibitor | 4–8 mg/kg IV every 4 weeks; or 162 mg SC every 1–2 weeks | Hepatitis B/C serology, TB screening; lipid panel; LFTs | LFTs, lipid panel, CBC, signs of infection; note: may suppress CRP/ESR (unreliable for monitoring inflammation) | Infection risk, hepatotoxicity, hyperlipidemia, GI perforation (rare), neutropenia |
Diagnostic Approach to Suspected Neurorheumatologic Disease
| Evaluation | Key Tests | Relevance |
|---|---|---|
| Serologic markers | RF, anti-CCP, ANA, ANCA (PR3/MPO), serum IgG4, IgG subclasses, complement levels, cryoglobulins | Disease-specific biomarkers; elevated serum IgG4 alone is not diagnostic of IgG4-RD |
| Inflammatory markers | ESR, CRP | Elevated in ~80% of rheumatoid meningitis; may be suppressed by tocilizumab |
| CSF analysis | Cell count, protein, glucose, cytology, flow cytometry, oligoclonal bands, CSF anti-CCP (if RA meningitis suspected) | Helps differentiate inflammatory from infectious etiologies; CSF anti-CCP may support RA meningitis diagnosis |
| MRI brain and spine | Pre- and post-contrast sequences; evaluate for pachymeningeal enhancement, leptomeningeal disease, mass lesions, cord compression | Pachymeningitis pattern seen in RA, IgG4-RD, GPA, relapsing polychondritis |
| Tissue biopsy | Meningeal or mass lesion biopsy with IgG4 staining, IgG4:IgG ratio | Gold standard for IgG4-RD; also valuable for excluding infection and malignancy |
| Systemic imaging | CT chest/abdomen/pelvis, PET-CT | Screen for systemic IgG4-RD involvement, vasculitis, malignancy |
References
- McCombe JA. Neurologic manifestations of rheumatologic disorders. Continuum (Minneap Minn). 2024;30(4):1189-1225.
- Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. 2020;16(12):702-714.